Comparison of the immunogenicity and safety among COVID-19 vaccines ChadOx-1, CoronaVac and BNT162b2 in systemic lupus erythematosus (SLE) patients: a prospective cohort.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ribeiro Priscila Dias Cardoso, Peixoto Flavia Maria Matos Melo Campos, Reis-Neto Edgard Torres Dos, Pileggi Gecilmara Salviato, Bellei Nancy Cristina Junqueira, Pinheiro Marcelo de Medeiros, Magalhães Vanessa de Oliveira, Biegelmeyer Erika, Trolese André Gustavo Cunha, Silva de Souza Alexandre Wagner, Kayser Cristiane, Valim Valéria, Machado Ketty Lysie Libardi Lira, Lirio Maressa Barbosa Beloni, de Oliveira Juliana Ribeiro, de Carvalho Andrea Teixeira, Vieira de Rezende Rodrigo Poubel, Guedes de Melo Ana Karla, Vieira Rejane Maria Rodrigues de Abreu, Cruz Vitor Alve, Angelina de Souza Viviane, Ferreira Gilda Aparecida, Ribeiro Sandra Lúcia Euzébio, Monticielo Odirlei, Xavier Ricardo Machado, Sartori Natalia Sarzi, Sato Emilia Inoue
Аннотация
METHODS: Prospective study including SLE patients who received a primary schedule to COVID-19 vaccination between May and August 2021. Immunogenicity, events supposedly attributable to vaccination or immunization (ESAVI) and disease activity were assessed at baseline and after each vaccine dose.
RESULTS: 121 SLE patients were included in the cohort, 88 in the immunogenicity analysis and 118 in the safety analysis. The groups were homogenous concerning sex, age, and comorbidities. Seropositivity after two doses of vaccines was similar between CoronaVac (68%), ChadOx1 (80,6%) and BNT162b2 (88%) (p=0.231). However, CoronaVac and ChadOx-1 presented lower titers in comparison with BNT162b2. Regarding ESAVI, the most frequent reported following first and second vaccine doses were, respectively: injection site pain (65.2%/41.1%), headache (50.9%/29.9%) and arthralgia (37.5%/22.5%). Fever and myalgia were more related to ChAdOx1 than CoronaVac (23.3 vs. 5.0%; p=0.025). There was no difference in MEX-SLEDAI between vaccine platforms. No serious ESAVI were reported.
CONCLUSION: After two doses, the three COVID-19 vaccine platforms induced a significant increase in antibody titers against SARS-CoV-2. Patients who received BNT162b2 exhibited a higher serological response compared to the other vaccines. All three vaccine platforms demonstrated a favorable safety profile, with no serious ESAVI or worsening of disease activity.
CLINICAL TRIAL NUMBER: The study was registered in The Brazilian Registry of Clinical Trials (ReBEC) in 04/14/2021 with code RBR-108fyykd.